PMGC Holdings (ELAB) Current Assets (2022 - 2026)
PMGC Holdings' (ELAB) quarterly Current Assets came in at $20.8 million in Q2 2026, up 185.27% year-over-year from $7.3 million in Q2 2025, and up 27.13% quarter-over-quarter from $16.4 million in Q1 2026.
Analysis
PMGC Holdings (ELAB) Current Assets (2022 - 2026) Analysis & Trends
PMGC Holdings has disclosed Current Assets across 5 years of filings, most recently posting $20.8 million for Q2 2026.
- In Q2 2026, Current Assets rose 185.27% year-over-year to $20.8 million; the TTM figure through Jun 2026 stood at $20.8 million (up 185.27% YoY), while the FY2025 annual figure was $6.9 million, up 13.56% from the prior year.
- Current Assets came in at $20.8 million for Q2 2026 at PMGC Holdings, up from $16.4 million in the prior quarter.
- In the past five years, Current Assets ranged from a high of $1.3 billion in Q3 2023 to a low of $1.6 million in Q4 2022.
- Average Current Assets over 5 years is $105.4 million, with a median of $6.9 million recorded in 2025.
- Year-over-year, Current Assets slumped 99.36% in 2024 and surged 259.55% in 2025.
- Over 5 years, Current Assets stood at $1.6 million in 2022, then soared by 217.11% to $4.9 million in 2023, then climbed by 23.0% to $6.1 million in 2024, then rose by 13.56% to $6.9 million in 2025, then surged by 203.19% to $20.8 million in 2026.
- Per Business Quant data, the three most recent Current Assets figures were $20.8 million in Q2 2026, $16.4 million in Q1 2026, and $6.9 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 207.11 Bn | 193.12 Bn | 7.24 Bn | 34.96 Bn |
| 2 | Gilead Sciences | 178.91 Bn | 175.73 Bn | 6.22 Bn | 13.95 Bn |
| 3 | Vertex Pharmaceuticals | 131.35 Bn | 123.50 Bn | 2.84 Bn | 12.54 Bn |
| 4 | Regeneron Pharmaceuticals | 81.84 Bn | 73.85 Bn | 3.93 Bn | 18.45 Bn |
| 5 | Argenx Se | 61.06 Bn | 55.87 Bn | 1.37 Bn | 8.07 Bn |
| 6 | Moderna | 53.08 Bn | 47.94 Bn | 52.00 Mn | 5.82 Bn |
| 7 | Alnylam Pharmaceuticals | 33.32 Bn | 30.01 Bn | 992.69 Mn | 4.62 Bn |
| 8 | Biogen | 31.70 Bn | 30.41 Bn | 1.96 Bn | 7.31 Bn |
| 9 | Roivant Sciences | 29.48 Bn | 29.48 Bn | 1.16 Mn | 4.74 Bn |
| 10 | PMGC Holdings | 2.23 Mn | -16.56 Mn | 385,691.00 | 20.83 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 20.83 Mn |
| Mar 31, 2026 | 16.39 Mn |
| Dec 31, 2025 | 6.87 Mn |
| Sep 30, 2025 | 9.77 Mn |
| Jun 30, 2025 | 7.30 Mn |
| Mar 31, 2025 | 6.82 Mn |
| Dec 31, 2024 | 6.05 Mn |
| Sep 30, 2024 | 8.23 Mn |
| Jun 30, 2024 | 2.03 Mn |
| Mar 31, 2024 | 3.14 Mn |
| Dec 31, 2023 | 4.92 Mn |
| Sep 30, 2023 | 1.28 Bn |
| Dec 31, 2022 | 1.55 Mn |